company background image
4105 logo

TTY Biopharm TPEX:4105 Stock Report

Last Price

NT$74.50

Market Cap

NT$18.4b

7D

2.5%

1Y

-11.8%

Updated

26 Nov, 2024

Data

Company Financials

TTY Biopharm Company Limited

TPEX:4105 Stock Report

Market Cap: NT$18.4b

4105 Stock Overview

Engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. More details

4105 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends5/6

TTY Biopharm Company Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for TTY Biopharm
Historical stock prices
Current Share PriceNT$74.50
52 Week HighNT$84.80
52 Week LowNT$69.50
Beta0.19
11 Month Change1.22%
3 Month Change-0.27%
1 Year Change-11.83%
33 Year Change9.40%
5 Year Change-12.66%
Change since IPO1,131.25%

Recent News & Updates

Recent updates

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Apr 02
Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Mar 15
Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Feb 25
Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Feb 07
TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

Jan 19
TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 10
What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

Dec 15
TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Nov 25
How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Shareholder Returns

4105TW PharmaceuticalsTW Market
7D2.5%5.4%2.0%
1Y-11.8%8.2%31.8%

Return vs Industry: 4105 underperformed the TW Pharmaceuticals industry which returned 8.2% over the past year.

Return vs Market: 4105 underperformed the TW Market which returned 31.8% over the past year.

Price Volatility

Is 4105's price volatile compared to industry and market?
4105 volatility
4105 Average Weekly Movement1.0%
Pharmaceuticals Industry Average Movement3.5%
Market Average Movement4.6%
10% most volatile stocks in TW Market8.1%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 4105 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 4105's weekly volatility (1%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1960n/an/awww.tty.com.tw

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre names for anti-cancer and supplementary treatments.

TTY Biopharm Company Limited Fundamentals Summary

How do TTY Biopharm's earnings and revenue compare to its market cap?
4105 fundamental statistics
Market capNT$18.42b
Earnings (TTM)NT$1.12b
Revenue (TTM)NT$5.83b

16.5x

P/E Ratio

3.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4105 income statement (TTM)
RevenueNT$5.83b
Cost of RevenueNT$2.42b
Gross ProfitNT$3.41b
Other ExpensesNT$2.29b
EarningsNT$1.12b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)4.50
Gross Margin58.47%
Net Profit Margin19.22%
Debt/Equity Ratio33.0%

How did 4105 perform over the long term?

See historical performance and comparison

Dividends

4.7%

Current Dividend Yield

78%

Payout Ratio